

RAISE Community Workshop Series Workshop 9
May 18, 2023

Speakers

Francisco De La Vega, DSc
Vice President of Hereditary Disease
Tempus



Francisco De La Vega is Vice President of Hereditary Disease at Tempus, where he is developing germline genetic tests and conducts research on the links between genetic ancestry and cancer genomic profiles. Francisco is an experienced technical leader in the life sciences tools industry, having spent over a decade at Applied Biosystems/ Life Technologies developing several successful genetic analysis products, and more recently contributing to technology start-up companies focused on bringing genome sequencing into the clinic. He is an internationally recognized geneticist and computational biologist and has participated in several breakthrough international projects including the 1000 Genomes Project, the Genome-in-a-Bottle Consortium, and the International Cancer Genome Consortium. Francisco has co-authored more than 150 scientific publications, including papers in top journals such as Nature, Nature Genetics, Science, Genome Research and others, which have received over 40,000 citations in total. He is also an Adjunct Professor in the Department of Biomedical Data Science at the Stanford University School of Medicine.

Ali Mokdad, PhD
Professor
Chief Strategy Officer of Population Health
Associate Chair for Collaboration
Associate Chair for Equity
University of Washington



Dr. Ali H. Mokdad is a Professor of Health Metric Science at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington and the vice chair of the Executive Council for the Population Health, launched by UW President Ana Mari Cauce to create a shared vision for improving the health and well-being of populations locally and around the world. IHME was founded in 2007 at the University of Washington to provide better evidence to improve health globally by guiding health policy and funding. As a public health researcher, Professor Mokdad has published ground breaking work on local-level disease trends and some of the leading risk factors for poor health. His work on obesity is among the most highly cited in the field. As the Director of Middle Eastern Initiatives for IHME, Professor Mokdad is building IHME's presence in the Middle East through new research projects, dissemination and uptake of IHME's methods and results, and consultation with regional leaders in

population health. Prof. Mokdad has published more than 450 articles and numerous reports. He has received several awards, including the Global Health Achievement Award for his work in Banda Aceh after the tsunami, the Department of Health and Human Services Honor Award for his work on flu monitoring, and the Shepard Award for outstanding scientific contribution to public health for his work on BRFSS. He received his BS in Biostatistics from the American University of Beirut and his PhD in Quantitative Epidemiology from Emory University.

Cleo A. Ryals, PhD
Senior Director and Head of Health Equity Research
Flatiron Health



Dr. Cleo A. Ryals is the Head of Health Equity Research at Flatiron Health, where she is tasked with developing and executing Flatiron’s company-wide health equity strategy with the goal of advancing cancer health equity through real-world evidence generation. Dr. Ryals is a health services researcher by training with expertise in cancer health equity, real-world data and evidence generation, health equity research methodology and data analytics, clinical trial diversity, and community engagement. She is a nationally recognized and highly sought after health equity researcher and leader with over 80 publications on topics related to health equity and oncology care. Prior to joining Flatiron Health, Dr. Ryals was a tenured Associate Professor of Health Policy and Management at the UNC Chapel Gillings School of Global Public Health, where she built substantial health equity research and training programs and was the Founding Director of the the Centering Racial Equity in Data Science (CREDS) Initiative at the UNC Lineberger Comprehensive Cancer Center. Dr. Ryals has also held positions within multiple federal offices/agencies, including the former United States Senate Office of Barack Obama, the Office of the National Coordinator for Health Information Technology, and the Government Accountability Office. In 2019, Dr. Ryals was recognized as a ‘40 Under 40’ Leader in Minority Health by the National Minority Quality Forum and Congressional Black Caucus. Dr. Ryals received her bachelor’s degree in Psychology and Biology from the University of Miami and her doctoral degree in Health Policy from Harvard University.

Krystal Tsosie, PhD, MPH, MA
Indigenous Geneticist-Bioethicist
Assistant Professor
School of Life Sciences, Arizona State University



Dr. Krystal Tsosie (Diné/Navajo Nation) is an Indigenous geneticist-bioethicist and Assistant Professor in the School of Life Sciences at Arizona State University. As an advocate for Indigenous genomic data sovereignty, she co-founded the first US Indigenous-led biobank, a 501c3 nonprofit research institution called the Native BioData Consortium. Her research can be encapsulated in two main foci: Indigenous population genetics and bioethics. In particular, she focuses on bioethical engagement of Indigenous communities in genomics and data science to build trust. As a whole, her interest is in integrating genomic and data approaches to assess Indigenous variation contributing to health inequities. She began her research career at the laboratory bench, where she developed and patented a combined targeted ultrasound imaging and chemotherapeutic drug delivery device for treating early metastases in cancer. Upon seeing the disparities in emerging genomics technologies, she switched fields to genetic epidemiology, public health, and bioethics. Her first master's degree in Bioethics at Arizona State University focused on the cultural implications of genetics in Native American communities. She added biostatistical knowledge and computational programming in large genomics datasets earning her second master's degree in Public Health (genetic epidemiology) at Vanderbilt University, where she studied disparities in uterine fibroids in African American women. She has co-led an ongoing longitudinal genetics study in a North Dakota Tribal community. This project serves as one of few examples of community-based participatory research involving genetics in an Indigenous tribal nation. Her research and educational endeavors have received increasing national and international media attention as scientists worldwide are understanding the importance of equitable, community-based engagement models and the importance of Indigenous genomic data sovereignty. Her work has been covered by popular media outlets including PBS NOVA, The Washington Post, NPR, New York Times, The Atlantic, Forbes, and Boston Globe. She currently serves on the Government Policy and Advocacy Committee for the American Society of Human Genetics and the National Academy of Medicine Announces Committee on Emerging Science, Technology, and Innovation. She is a current Global Chair in ENRICH (Equity for Indigenous Research and Innovation Coordinating Hub), which focuses on enhancing Indigenous rights to develop, control, and govern Indigenous data and supports participation in STEM and in digitally-enabled futures.

Moderator

Phillip Febbo, MD
Chief Medical Officer
Illumina




Dr. Phil Febbo was appointed as Chief Medical Officer of Illumina in March 2018. In this role, he is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice. Dr. Febbo has a successful track record of translational research, clinical excellence, and for embedding molecular insights into clinical care. Immediately before joining Illumina, Dr. Febbo served as CMO of Genomic Health. Prior to his five years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. Before joining the faculty of UCSF as an associate professor in 2010, Dr. Febbo worked at Duke University Medical Center’s Institute of Genome Sciences and Policy. He completed his internal medicine residency at the Brigham and Women’s Hospital, and his fellowship in oncology at the Dana-Farber Cancer Institute. After which he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub’s laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). Throughout his career, Dr. Febbo has served as a primary investigator for the Translational Research Program of The Alliance, an NCI-supported cooperative group, where his work focused on incorporating biomarkers into large clinical trials. He holds a bachelor’s degree in Biology from Dartmouth College and a medical degree from UCSF. Dr. Febbo joined the Reagan-Udall Foundation for the FDA Board of Directors in 2021.

RAISE FDA & FDA Foundation Team

RDML Richardae Araojo, PharmD, MS

Associate Commissioner for Minority Health, Director

Office of Minority Health and Health Equity, U.S. Food and Drug Administration



Rear Admiral Richardae Araojo, PharmD, MS, serves as the Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity at the U.S. Food and Drug Administration (FDA). In this role, RDML Araojo provides leadership, oversight, and direction on minority health and health disparity matters for the Agency. RDML Araojo previously served as the Director of the Office of Medical Policy Initiatives in FDA’s Center for Drug Evaluation and Research (CDER), where she led a variety of broad-based medical and clinical policy initiatives to improve the science and efficiency of clinical trials and enhance professional and patient labeling. RDML Araojo joined FDA in 2003, where she held several positions in CDER. RDML Araojo received her doctoral degree in Pharmacy from Virginia Commonwealth University, completed a Pharmacy Practice Residency at University of Maryland, and earned a master’s degree in Pharmacy Regulation and Policy from the University of Florida.



Carla Rodriguez-Watson, PhD, MPH
Director of Research

Reagan-Udall Foundation for the FDA



Dr. Carla Rodriguez-Watson is the Director of Research for the Reagan-Udall Foundation for the FDA. Dr Rodriguez-Watson is focused on continuously developing and enhancing a portfolio of work that leverages real-world data and experiences to inform and conduct clinical and post-market drug safety and effectiveness studies. Projects include those focused on developing and advancing frameworks and tools to systematically describe data sources and methods for use in pre and post-market studies of product safety and effectiveness; as well as the the Innovation in Medical Evidence, Development

and Surveillance (IMEDS) Program – where such tools can be leveraged. IMEDS leverages a distributed network and tools developed by the FDA’s Sentinel initiative to design and execute post-market drug safety studies in a network of 9 healthcare systems representing over 111 M persons. Dr. Rodriguez-Watson brings her extensive background in public health surveillanncce and health outcomes research to this work. She earned her doctoral degree in Epidemiology from the University of Washington School of Public Health, her master’s degree in Public Health from Columbia University Mailman School of Public Health, and her bachelor’s degree from Rutgers University.

Susan C. Winckler, RPh, Esq.
CEO

Reagan-Udall Foundation for the FDA



Susan C. Winckler is CEO of the Reagan-Udall Foundation for the FDA, the non-profit organization created by Congress to advance the mission of the FDA. Prior to accepting the Foundation post, she served as President of Leavitt Partners Solutions, a healthcare strategy firm founded by Gov. Michael O. Leavitt, former Secretary of the U.S. Department of Health and Human Services. Winckler directly advised C-suite executives of a wide range of organizations on public policy and regulation, business strategy, investments, and other major business matters. As Chief of Staff for the U.S. Food and Drug Administration (2007-2009), she managed the Commissioner’s Office, served both Republican and Democratic commissioners as their senior-most staff adviser, analyzed complex policy challenges and represented FDA with myriad government entities and external stakeholders. Her earlier career service included more than a decade at the American Pharmacists Association in a series of positions of increasing responsibility.